Department Of Pharmacology

New structural findings reveal how "gatekeeper" proteins participate in the secretion systems bacteria use to infect host cells. Read More

Vanderbilt researchers have discovered a new target for the prevention of atherosclerotic plaque development and cardiovascular disease. Read More

Peter Doherty, Ph.D., had some advice for young scientists at last week’s Flexner Discovery Lecture. The way to win a Nobel Prize, he said, “is to make a very big discovery first.” Read More

Defects in the production of certain receptors are linked to the pathogenesis of genetic epilepsies and fever-induced seizures. Read More

Nobel laureate Peter Doherty, Ph.D., who discovered how the immune system recognizes virus-infected cells, will deliver the next Flexner Discovery Lecture on Thursday, Oct. 2. Read More

Drugs developed at Vanderbilt could provide a new way to treat schizophrenia in a personalized way. Read More

A combination treatment delivered to the site of fractures may improve bone healing in patients with the genetic disease neurofibromatosis type-1. Read More

An enzyme therapy may prevent skeletal abnormalities associated with the genetic disorder neurofibromatosis type-1, Vanderbilt investigators have discovered. Read More

During her 13-year tenure as chair of Vanderbilt University’s Department of Pharmacology, Heidi Hamm, Ph.D., bolstered its international reputation, attracted 18 new faculty members and helped take it in new directions, such as drug discovery. Read More

A new compound that activates potassium channels could be used to treat disorders of glucose homeostasis. Read More

Electronic medical records linked to DNA biobanks are a valid resource for defining and understanding the genetic factors that contribute to drug response. Read More

Neuroscientist and biophysicist David Clapham, M.D., Ph.D., known for his studies of ion channels and cell signaling, will deliver the next Flexner Discovery Lecture on Thursday, April 3, in 208 Light Hall. Read More

A compound identified at Vanderbilt has therapeutic potential in protecting the kidney filter barrier. Read More

Vanderbilt researchers have discovered small molecules that turn off cancerous Ras signals in a new way. Read More

Variation in the gene for the beta-1 adrenergic receptor increases the risk that a patient will have an abnormal heart rhythm after cardiac surgery. Read More

An association between rigid-compulsive behaviors and gastrointestinal symptoms in autism spectrum disorder may point to a common biological pathway that impacts both the brain and the gut. Read More

Vanderbilt researchers are studying how mutations in the receptor for light, rhodopsin, cause light blindness. Read More

Vanderbilt investigators used an in vivo screen in zebrafish to identify a potential new anti-cancer drug. Read More

New mass spectrometry imaging methods will enable studies of the distribution and identification of membrane proteins directly within tissues. Read More

A biomarker for oxidative stress is elevated in patients with both autism spectrum disorder and gastrointestinal dysfunction, suggesting opportunities for individualized approaches to clinical care. Read More